What is the recommended antimicrobial treatment for an adult with enteric fever (typhoid/paratyphoid) who has no known drug allergies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Antimicrobial Treatment for Enteric Fever in Adults

For adults with enteric fever and no drug allergies, azithromycin 500-1000 mg orally daily for 7 days is the preferred first-line treatment, particularly for infections acquired from South Asia where fluoroquinolone resistance exceeds 70%. 1, 2

Treatment Selection Based on Geographic Origin

Infections from South Asia (India, Pakistan, Bangladesh, Nepal)

  • Start azithromycin 500-1000 mg orally daily for 7 days as empiric therapy due to widespread fluoroquinolone resistance (87-98% of isolates) 1, 3
  • Azithromycin demonstrates superior outcomes compared to fluoroquinolones in regions with drug-resistant strains, with lower clinical failure rates (OR 0.48,95% CI 0.26-0.89) and shorter hospital stays (1 day reduction) 4, 5
  • Avoid ciprofloxacin empirically for South Asian cases—over 70% of S. Typhi isolates from this region are fluoroquinolone-resistant 4, 1
  • Pakistan has additional concern for extensively drug-resistant (XDR) strains (64% of isolates), which are resistant to fluoroquinolones AND third-generation cephalosporins 3

Infections from Sub-Saharan Africa

  • Ciprofloxacin 500 mg orally twice daily for 7-10 days remains an acceptable alternative for African-acquired cases, as fluoroquinolone resistance rates are lower 4, 2, 6
  • Fluoroquinolones achieve fever clearance within 4 days, cure rates >96%, and low relapse rates (<8%) when organisms are susceptible 4

Severe or Hospitalized Cases

  • Ceftriaxone 2 g IV daily for 5-7 days for patients with sepsis, altered mental status, or inability to tolerate oral therapy 1, 2
  • Switch to oral azithromycin once clinically improved and afebrile for 24 hours to complete 7-14 days total treatment 1
  • Ceftriaxone shows lower treatment failure compared to gatifloxacin in culture-confirmed cases (HR 0.24,95% CI 0.08-0.73) 4

Critical Management Steps

Before Starting Antibiotics

  • Obtain blood cultures immediately—highest yield within first week of symptoms (40-80% sensitivity) 4, 2
  • Collect stool and urine cultures if sepsis suspected, as these become positive after the first week 4
  • Do NOT delay treatment in clinically unstable patients; start empiric therapy after cultures obtained 4, 2

Antibiotic Susceptibility Testing Pitfalls

  • Never rely on ciprofloxacin disc testing alone to determine fluoroquinolone susceptibility 4
  • The organism must ALSO be sensitive to nalidixic acid on disc testing to be considered truly fluoroquinolone-susceptible 4
  • Azithromycin susceptibility testing is not readily available, but resistance remains rare (<3% globally) 4

Alternative Regimens (When First-Line Options Unavailable)

For Susceptible Isolates

  • Ofloxacin 400 mg orally twice daily for 7-10 days if confirmed fluoroquinolone-susceptible 2
  • Chloramphenicol may be considered only as last resort when no other options available, though resistance patterns have changed 4, 1

Oral Step-Down Options

  • Cefixime 400 mg orally once daily can be used but has higher treatment failure rates (4-37.6%) compared to other options 4
  • Azithromycin remains preferred oral follow-on agent for fluoroquinolone-resistant cases 4

Treatment Duration and Monitoring

  • Complete 7-14 days of appropriate antibiotic therapy to reduce relapse risk 4, 1
  • Azithromycin has lowest relapse rates (<3%) compared to ceftriaxone (<8%) and fluoroquinolones 4
  • Expect fever clearance within 4-5 days of appropriate therapy 4, 1
  • Narrow therapy based on susceptibility results when available 2

Common Pitfalls to Avoid

  • Do not assume all enteric fever is fluoroquinolone-susceptible—resistance is now the norm in South Asia, not the exception 4, 1, 3
  • Do not use cefixime as first-line empiric therapy—it has unacceptably high failure rates and should be reserved for confirmed susceptible isolates 4
  • Do not stop antibiotics early—inadequate treatment duration increases relapse risk, which can occur up to one month after initial treatment 7
  • Do not forget to consider upper GI bleeding—though rare, gastric ulcers can develop and cause life-threatening hemorrhage 7

Special Considerations

Infants Under 3 Months

  • Use third-generation cephalosporin (ceftriaxone) rather than azithromycin or fluoroquinolones 1, 8

Asymptomatic Contacts

  • Do not offer empiric treatment to asymptomatic contacts; implement infection control measures instead 2

Persistent Symptoms

  • Reassess fluid/electrolyte balance, nutritional status, and consider treatment failure or complications 2
  • Repeat blood cultures if fever persists beyond 5 days of appropriate therapy 1

References

Guideline

Treatment of Enteric Fever in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Enteric Fever

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016-2019.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Empiric Antibiotics for Fever and Bloody Diarrhea

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.